ClinicalTrials.gg
CompletedNCT01553539Updated Jul 5, 2018Results posted

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

A Phase 2 interventional study of therapeutic angiotensin-(1-7) and laboratory biomarker analysis in Bone Cancer, Chondrosarcoma and Clear Cell Sarcoma of the Kidney, sponsored by Wake Forest University Health Sciences. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-05.

Sponsored by Wake Forest University Health Sciences · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This phase II trial studies how well therapeutic angiotensin-(1-7) works as second-line therapy or third-line therapy in treating patients with metastatic sarcoma that cannot be removed by surgery. Therapeutic angiotensin-(1-7) may stop the growth of sarcoma by blocking blood flow to the tumor.

Funding Source - FDA Office of Orphan Drug Products (OOPD)

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the response rate of chemotherapy-refractory sarcomas to 20 mg per day of single-agent Ang(Angiotensin)-(1-7) or 10 mg per day of single-agent Ang-(1-7) if excessive toxicity is observed at the 20 mg dose.

II. To evaluate toxicities associated with single-agent Ang-(1-7) when given to patients with chemotherapy-refractory sarcomas.

SECONDARY OBJECTIVES:

I. To assess time to progression (TTP) and overall survival (OS) in patients treated with Ang-(1-7).

II. To evaluate accumulation of Ang-(1-7) after 21 days of continuous treatment and quantify changes in plasma levels of angiogenic peptides including placental growth factor (PlGF).

OUTLINE:

Patients receive therapeutic angiotensin-(1-7) subcutaneously (SC) once daily in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

02

Conditions studied

  • Bone Cancer
  • Chondrosarcoma
  • Clear Cell Sarcoma of the Kidney
  • Metastatic Osteosarcoma
  • Ovarian Sarcoma
  • Recurrent Adult Soft Tissue Sarcoma
  • Recurrent Osteosarcoma
  • Recurrent Uterine Sarcoma
  • Stage III Adult Soft Tissue Sarcoma
  • Stage III Uterine Sarcoma
  • Stage IV Adult Soft Tissue Sarcoma
  • Stage IV Uterine Sarcoma
03

In context

Bone Neoplasms

258 studies on the registry are indexed under Bone Neoplasms; 68 are open to participants now.

This study's enrollment of 20 is below the median of 44 across 163 interventional studies indexed under Bone Neoplasms.

Browse Bone Neoplasms studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,351 studies on the registry; 201 are open to participants now.

Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a or cytologically confirmed sarcoma that is or unresectable and have progressed despite 1 or 2 prior treatment regimens with chemotherapy or targeted anti-cancer agents such as imatinib
  • Prior treatment: >= 4 weeks since completion of radiation or chemotherapy, except for >= 6 weeks for Melphalan, nitrosoureas, or mitomycin-C
  • (ECOG) performance status =\< 2
  • >= 1,500/Microliter (mcL)
  • >= 100,000/mcL
  • Total =\< 2 mg/dL
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) \< 3 X upper limit or normal ()
  • Estimated (est.) > 30 mL/min
  • , defined as at least one lesion that can be accurately measured in at least one dimension as > 10 mm
  • Women of and men must agree to use adequate (hormonal or double-barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Patients may not be receiving any other agents for cancer treatment
  • Patients with evidence of bleeding diathesis are ineligible
  • No concurrent treatment with angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs)
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension or hypotension, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant and nursing women are excluded from this study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment (antiangiogenesis therapy)

    Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.

    Drug: therapeutic angiotensin-(1-7) · Other: laboratory biomarker analysis

Interventions

06

What researchers measure

Primary outcomes

  1. Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response

    'Activity' will be operationalized using objective tumor response, which will be estimated as the proportion of partial and complete responders (according to Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) among all evaluable patients. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Approximately 1 year

  2. Number of Participants Who Experienced Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0

    See the adverse event tables for specifics.

    Time frame: Approximately 1 year

Secondary outcomes

  1. Time to Disease Progression

    Time frame: Approximately 5 years

  2. Overall Survival

    Time frame: Approximately 5 years

  3. Plasma Levels of Angiogenic Peptides Including Placental Growth Factor (PlGF)

    Time frame: Baseline and Day 22

07

Results

Posted Jan 30, 2014

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Antiangiogenesis Therapy)
Started20
Completed20
Not completed0

Outcome measures

PrimaryAntitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response

'Activity' will be operationalized using objective tumor response, which will be estimated as the proportion of partial and complete responders (according to Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) among all evaluable patients. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Approximately 1 year
Reported as:
Number · participants
Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response
participantsTreatment (Antiangiogenesis Therapy)
Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response0
PrimaryNumber of Participants Who Experienced Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0

See the adverse event tables for specifics.

Time frame:
Approximately 1 year
Reported as:
Number · Participants experiencing adverse events
Number of Participants Who Experienced Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
Participants experiencing adverse eventsTreatment (Antiangiogenesis Therapy)
Number of Participants Who Experienced Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.020
SecondaryTime to Disease Progression
Time frame:
Approximately 5 years
Reported as:
Median · months
Time to Disease Progression
monthsTreatment (Antiangiogenesis Therapy)
Time to Disease Progression2.7 (1.4 to 4.1)
SecondaryOverall Survival
Time frame:
Approximately 5 years
Reported as:
Median · months
Overall Survival
monthsTreatment (Antiangiogenesis Therapy)
Overall Survival10.2 (5.3 to 18.3)
SecondaryPlasma Levels of Angiogenic Peptides Including Placental Growth Factor (PlGF)
Time frame:
Baseline and Day 22
Reported as:
Median · pg/mL
Plasma Levels of Angiogenic Peptides Including Placental Growth Factor (PlGF)
pg/mLTreatment (Antiangiogenesis Therapy)
Ang-(1-7) Baseline18.4 ± 385.0
Ang-(1-7) Day 2241.2 ± 2840.0
Ang II Baseline21.3 ± 11.5
Ang II Day 2231.5 ± 26.5
Ang I Baseline22.5 ± 127
Ang I Day 2217.5 ± 52.7
VEGF Baseline65.6 ± 66.4
VEGF Day 2249.6 ± 43.0
PIGF Baseline4.3 ± 2.1
PIGF Day 223.0 ± 1.7

Adverse events

Collected over Duration of treatment, up to one year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Antiangiogenesis Therapy)—11/20 (55%)20/20 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventTreatment (Antiangiogenesis Therapy)
LymphopeniaInvestigations4/20
Obstruction, GU: UreterGeneral disorders3/20
Low HemoglobinInvestigations2/20
DyspneaRespiratory, thoracic and mediastinal disorders2/20
Pleural effusion (non-malignant)Respiratory, thoracic and mediastinal disorders2/20
hyperglycemiaInvestigations2/20
hyponatremiaInvestigations2/20
hypoalbuminemiaInvestigations2/20
Thrombosis/thrombus/embolismVascular disorders2/20
HypoxiaInvestigations2/20
Most frequent other events
Showing 10 of 57
Most frequent other events
EventTreatment (Antiangiogenesis Therapy)
Low HemoglobinInvestigations14/20
hyperglycemiaInvestigations14/20
LymphopeniaInvestigations12/20
Low WBCInvestigations9/20
DyspneaRespiratory, thoracic and mediastinal disorders9/20
hypokalemiaInvestigations9/20
Edema: limbVascular disorders9/20
NauseaGastrointestinal disorders8/20
FatigueGeneral disorders8/20
CoughRespiratory, thoracic and mediastinal disorders8/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment (Antiangiogenesis Therapy)
<=18 years0
Between 18 and 65 years18
>=65 years2
Age, Continuous
Age, Continuous(years)Treatment (Antiangiogenesis Therapy)
Mean51.4 ± 14.9
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Antiangiogenesis Therapy)
Female9
Male11
Region of Enrollment
Region of Enrollment(participants)Treatment (Antiangiogenesis Therapy)
United States20
08

Study locations

1 site
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01553539
Responsible party
Sponsor
First posted
Mar 14, 2012
Start date
Oct 2009
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Jan 30, 2014
Last update
Jul 5, 2018

Study contacts

William Petty
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Talfirastide

Start the discussion